Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novavax stock dips 14% on the heels of Q4 announcement

By Brian Buntz | March 3, 2021


NovavaxNovavax announced fourth-quarter earnings that fell below analysts’ projections, but the company could make more than 2 billion doses of its COVID-19 vaccine annually.  

The company’s vaccine demonstrated 90% efficacy in a Phase 3 trial in the U.K.

The company’s outlook for the rest of the year depends largely on FDA’s authorization of its COVID-19 vaccine. It is also developing a flu vaccine. 

The company’s CEO Stanley C. Erck says authorization could come as soon as May. 

The Gaithersburg, Md.–based vaccine developer announced revenue of $276.7 million, which was more than 3000% more year-over-year. The company, however, still had a loss of –$2.70 per share, representing a fall of 138.94% over a year earlier. 

Analysts had expected negative EPS of –$1.49 and revenue of $304.9 million. 

“The past year has been a whirlwind. We have completely changed the company in ways that would normally take several years to accomplish,” said Novavax CEO Stan Erck in an earnings call. “While many businesses in the world have slowed down due to the pandemic, we’ve done the opposite. Everything about our company has changed.” 

While the company did not release guidance, the company’s president of R&D, Gregory Glenn, said he expected to complete the filing for an EUA in the second quarter of the year. 

Last year, the U.S. Health and Human Services Dept. and Defense Dep. agreed to support Novavax worth $1.6 billion to support the development and manufacture of its COVID-19 vaccine candidate.

Since Monday, the company’s stock has fallen about $34 per share, dropping –14.27% to $205.99 per share.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50